Dr. Mei Dong
Claim this profileLegacy Good Samaritan Hospital and Medical Center
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
39 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
HER2 negative
2Cancer
HER2 positive
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Mei Dong is currently running
Ribociclib vs. Palbociclib
for Breast Cancer
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.
Recruiting4 awards Phase 311 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Mei Dong
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Mei Dong has experience with
- Pembrolizumab
- Cabozantinib S-malate
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
- Biospecimen Collection
Breakdown of trials Mei Dong has run
Breast Cancer
Cancer
Lung Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mei Dong specialize in?
Mei Dong focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Mei Dong currently recruiting for clinical trials?
Yes, Mei Dong is currently recruiting for 10 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Mei Dong has studied deeply?
Yes, Mei Dong has studied treatments such as Pembrolizumab, Cabozantinib S-malate, Cyclophosphamide.
What is the best way to schedule an appointment with Mei Dong?
Apply for one of the trials that Mei Dong is conducting.
What is the office address of Mei Dong?
The office of Mei Dong is located at: Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon 97210 United States. This is the address for their practice at the Legacy Good Samaritan Hospital and Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.